Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Alvimopan for Opioid-Induced Bowel Dysfunction
NCT00241722Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced bowel dysfunction (OIBD) comparing Alvimopan 0.5 mg BID with Placebo (2 arms). Primary endpoint: Long-term safety and tolerability at 12 months. Started Aug 2005; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT00241722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241722.